Technical Analysis for RGEN - Repligen Corporation
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Doji - Bearish? | Reversal | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| NR7 | Range Contraction | 3.13% | |
| Narrow Range Bar | Range Contraction | 3.13% | |
| Wide Bands | Range Expansion | 3.13% | |
| 180 Bearish Setup | Bearish Swing Setup | 2.71% | |
| Wide Bands | Range Expansion | 2.71% | |
| Oversold Stochastic | Weakness | 2.71% | |
| Slingshot Bearish | Bearish Swing Setup | 1.34% |
| Alert | Time |
|---|---|
| 2x Volume Pace | about 20 hours ago |
| 1.5x Volume Pace | about 20 hours ago |
| 10 DMA Support | about 20 hours ago |
| Rose Above 10 DMA | about 20 hours ago |
| Up 3% | about 20 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 07/31/2024
Repligen Corporation Description
Repligen Corporation, a life sciences company, engages in the development, production, and commercialization of consumable products used in the process of manufacturing biological drugs. Its bioprocessing products are sold to various life sciences and biopharmaceutical companies worldwide. The company manufactures Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. It also supplies various growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, the company develops and markets its OPUS brand series of pre-packed ‘plug-and-play' chromatography columns, and provides ELISA test kits to ensure final product quality. Further, Repligen has a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and a orphan drug candidate in Phase 1 development. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Natural Sciences Monoclonal Antibody 3 D Orphan Drug Consumable Products Chromatography Imaging Agent Bioprocessing Cell Culture Bioprocess Drug Manufacturing Growth Factor Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 211.13 |
| 52 Week Low | 110.46 |
| Average Volume | 670,608 |
| 200-Day Moving Average | 167.37 |
| 50-Day Moving Average | 153.82 |
| 20-Day Moving Average | 136.76 |
| 10-Day Moving Average | 126.09 |
| Average True Range | 5.78 |
| RSI (14) | 33.33 |
| ADX | 36.61 |
| +DI | 24.65 |
| -DI | 40.20 |
| Chandelier Exit (Long, 3 ATRs) | 142.47 |
| Chandelier Exit (Short, 3 ATRs) | 130.83 |
| Upper Bollinger Bands | 160.25 |
| Lower Bollinger Band | 113.28 |
| Percent B (%b) | 0.29 |
| BandWidth | 34.34 |
| MACD Line | -10.04 |
| MACD Signal Line | -9.66 |
| MACD Histogram | -0.3781 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 133.65 | ||||
| Resistance 3 (R3) | 133.65 | 131.44 | 132.54 | ||
| Resistance 2 (R2) | 131.44 | 129.75 | 131.44 | 132.17 | |
| Resistance 1 (R1) | 129.22 | 128.70 | 130.33 | 129.22 | 131.80 |
| Pivot Point | 127.01 | 127.01 | 127.57 | 127.01 | 127.01 |
| Support 1 (S1) | 124.79 | 125.32 | 125.90 | 124.79 | 122.20 |
| Support 2 (S2) | 122.58 | 124.27 | 122.58 | 121.83 | |
| Support 3 (S3) | 120.36 | 122.58 | 121.46 | ||
| Support 4 (S4) | 120.36 |
